--- title: "InnoCare Pharma Limited (688428.SH)" type: "Symbol" locale: "en" url: "https://longbridge.com/en/quote/688428.SH.md" symbol: "688428.SH" name: "InnoCare Pharma Limited" industry: "Biotechnology" datetime: "2026-05-20T14:40:11.245Z" locales: - [en](https://longbridge.com/en/quote/688428.SH.md) - [zh-CN](https://longbridge.com/zh-CN/quote/688428.SH.md) - [zh-HK](https://longbridge.com/zh-HK/quote/688428.SH.md) --- # InnoCare Pharma Limited (688428.SH) ## Company Overview InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases in China. The company develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom’s macroglobulinemia, r/r marginal zone lymphoma, r/r diffuse large B-cell lymphoma (DLBCL)- MCD, r/r central nervous system lymphoma, combo w/MIL-62, systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder. It also developing ICP-B02 to treat CD20+B-cell malignancies; ICP-B05 to treat hemato-oncology; ICP-248 to treat chronic lymphocytic leukemia; ICP-332 to treat atopic dermatitis; ICP-488 to treat psoriasis; ICP-538 to treat autoimmune diseases; zurletrectinib (ICP-723) to treat neurotrophic tyrosine receptor kinase fusion positive cancers; ICP-189 to treat non-small cell lung cancer; and ICP-B05 to treat solid tumor. InnoCare Pharma Limited was incorporated in 2015 and is headquartered in Beijing, China. | Item | Detail | |------|--------| | Industry | Biotechnology | | Exchange | CN Market | | Website | [www.innocarepharma.com](https://www.innocarepharma.com) | ## Key Drivers > *AI-analyzed key factors driving this stock's performance* ## Longbridge Financial Score™: B > *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge* > Updated: 2026-05-20T04:30:09.000Z **Overall: B (0.33)** **Industry**: Biotechnology | Metric | Value | |--------|-------| | Industry Ranking | 5 / 81 | | Industry Median | C | | Industry Average | C | - **Style**: Growth - Stocks whose main business is in the growth stage. - **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns. **Multi Score**: B #### Style Score Score: | Indicator | Value | Rating | |-----------|-------|--------| | Revenue YoY | 105.92% | | | Net Profit YoY | 360.58% | | | P/B Ratio | 5.86 | | | Dividend Ratio | 0.00% | | #### Size Score Score: | Indicator | Value | Rating | |-----------|-------|--------| | Market Cap | 43133898707.83 | | | Revenue | 2526754715.61 | | #### Multi Score Score: B | Indicator | Value | Rating | |-----------|-------|--------| | ROE | 10.36% | B | | Profit Margin | 28.95% | A | | Gross Margin | 88.14% | A | | Revenue YoY | 105.92% | A | | Net Profit YoY | 360.58% | A | | Total Assets YoY | 10.30% | B | | Net Assets YoY | 8.82% | B | | Cash Flow Margin | 4.33% | D | | OCF YoY | 105.92% | A | | Turnover | 0.25 | D | | Gearing Ratio | 29.09% | B | ```chart-data:radar { "title": "Longbridge Financial Score - InnoCare Pharma Limited", "chart_type": "radar", "dimensions": [ { "name": "Style Score", "grade": "", "indicators": [ { "name": "Revenue YoY", "value": "105.92%", "rating": "" }, { "name": "Net Profit YoY", "value": "360.58%", "rating": "" }, { "name": "P/B Ratio", "value": "5.86", "rating": "" }, { "name": "Dividend Ratio", "value": "0.00%", "rating": "" } ] }, { "name": "Size Score", "grade": "", "indicators": [ { "name": "Market Cap", "value": "43133898707.83", "rating": "" }, { "name": "Revenue", "value": "2526754715.61", "rating": "" } ] }, { "name": "Multi Score", "grade": "B", "indicators": [ { "name": "ROE", "value": "10.36%", "rating": "B" }, { "name": "Profit Margin", "value": "28.95%", "rating": "A" }, { "name": "Gross Margin", "value": "88.14%", "rating": "A" }, { "name": "Revenue YoY", "value": "105.92%", "rating": "A" }, { "name": "Net Profit YoY", "value": "360.58%", "rating": "A" }, { "name": "Total Assets YoY", "value": "10.30%", "rating": "B" }, { "name": "Net Assets YoY", "value": "8.82%", "rating": "B" }, { "name": "Cash Flow Margin", "value": "4.33%", "rating": "D" }, { "name": "OCF YoY", "value": "105.92%", "rating": "A" }, { "name": "Turnover", "value": "0.25", "rating": "D" }, { "name": "Gearing Ratio", "value": "29.09%", "rating": "B" } ] } ] } ``` ## Valuation Analysis | Metric | Current | Industry Ranking | High | Median | Low | |--------|---------|-----------------|------|--------|-----| | PE (TTM) | 59.17 | 26/81 | 81.52 | 68.57 | 64.32 | | PB | 5.88 | 57/81 | 7.29 | 6.43 | 5.96 | | PS (TTM) | 17.13 | 66/81 | 37.99 | 30.90 | 25.87 | | Dividend Yield | 0.00% | - | - | - | - | ## Peer Comparison | Rank | Name | Profit | Growth | Operation | Security | Cash | Rating | | --- | --- | --- | --- | --- | --- | --- | --- | | 01 | Sunshine Guojian Pharmaceutical (688336.SH) | A | A | B | A | B | A | | 02 | AMOYTOP (688278.SH) | A | A | A | A | B | A | | 03 | BeOne Medicines (688235.SH) | B | A | B | C | A | B | | 04 | RemeGen (688331.SH) | A | A | C | C | B | B | | 05 | InnoCare Pharma (688428.SH) | B | A | D | B | B | B | ## Institutional View ### Analyst Rating Distribution > As of 2026-04-30T16:00:00.000Z Total Analysts: **4** | Rating | Count | Percentage | |--------|-------|-----------| | Buy | 3 | 75% | | Hold | 1 | 25% | ### Target Price Forecast | Metric | Price | |--------|-------| | Current Price | 24.49 | | Highest Target | 35.00 | | Lowest Target | 19.60 | ## References - [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/688428.SH/overview.md) - [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/688428.SH/norm.md) - [Related News](https://longbridge.com/en/quote/688428.SH/news.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**